Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2100541 | 0.91 | KDM4E (0.55) | TP53POLBDRD2TBXA2RMAPT | |
| SCHEMBL3140520 | 0.82 | LMNA (0.42) | TP53POLBTBXA2RMAPTLMNA | |
| SCHEMBL23997462 | 0.81 | DRD2 (0.75) | TP53DRD2TBXA2RMAPTLMNA | |
| SCHEMBL30336823 | 0.81 | DRD2 (0.75) | TP53DRD2TBXA2RMAPTLMNA | |
| SCHEMBL22955655 | 0.80 | DRD2 (0.51) | TP53POLBDRD2TBXA2RMAPT | |
| SCHEMBL2161533 | 0.79 | KDM4E (0.68) | TP53POLBMAPTLMNA | |
| SCHEMBL8285684 | 0.76 | MAPT (0.48) | POLBMAPTLMNAAGTR1AGTR2 | |
| SCHEMBL9198766 | 0.76 | AGTR1 (0.79) | DRD2TBXA2RAGTR1AGTR2 | |
| SCHEMBL30020641 | 0.76 | ACSS2 (0.47) | DRD2TBXA2RACSS2 | |
| SCHEMBL24900035 | 0.76 | ACSS2 (0.47) | DRD2TBXA2RACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163774-B2 | Antidiabetic agents; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-(4-Chlorobenzyl)-2-(3-aminopiperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzimidazole-6-carboxamide hydrochloride for example; use in combination with other antidiabetic, antilipemic agents | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | DPP8, GPR119, ABAT | TP53 4107/4885POLB 4330/4885DRD2 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.